Stiftung Forschung 3R - Startseite
Projekte


 

de | fr | en   Druckansicht

Projektverzeichnis

Testing and Diagnosis

ADJUVANTICITY

92-04Adjuvanticity of microbial-derived particles and synthetic analogs in vitro.
Padovan E., Prof. Dr., Instituto Gulbenkian de Ciência, Oerias, Portugal
 

ANTIBODY PRODUCTION TEST

74-00Validation of polymerase chain reaction assays as replacement of the Mouse Antibody Production (MAP) Test
Bootz F., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland
 

BIOACCUMULATION

141-14In-vitro alternatives to in-vivo bioconcentration-testing in fish: restricted to rainbow trout or broadly applicable ?
Segner, H., Prof., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Bern, Switzerland
 
108-07Cultured piscine hepatocytes as an in-vitro source of metabolic clearance data that is currently gleaned by in-vivo bioaccumulation testing in fish
Segner H., Prof. Dr., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Berne, Switzerland
 
100-06Development of an in-vitro system for modeling bioaccumulation of neutral, ionizable, and metabolically active organic pollutants in fish
Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 

BIOCOMPATIBILITY

DIAGNOSTIC APPROACHES

DIAGNOSTIC APPROACHES: BIOLOGICAL MATERIALS

DIAGNOSTIC APPROACHES: IMMUNO

85-03Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 

DIAGNOSTIC APPROACHES: MICROORGANISMS

48-96Utilization of a model of culture of human intestinal cell lines for the study of the pathogenicity of different strains of Clostridium difficile
Kraehenbuhl J.-P., Prof. Dr., Institut Suisse de Recherches Expérimentales sur le Cancer (ISREC), Switzerland
 

DIAGNOSTIC APPROACHES: MONOCLONAL ANTIBODIES

84-02Direct cloning of human antibodies from purified specific B-cells
Wirthmueller U., Dr., Institute of Immunology, University Hospital Bern, Switzerland
 

DIAGNOSTIC APPROACHES: PARASITES

85-03Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
79-01Screening methods for repellents and attachment deterrents for ticks in-vitro
Guerin P., PD Dr., Institute of Zoology, University of Neuchâtel, Switzerland
 
72-00Development and applications of an in vitro cultivation model for Neospora caninum tissue cyst formation
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 

DIAGNOSTIC APPROACHES: PYROGENS

52-96Development of an interleukin-1 (IL-1) assay with rabbit blood as an alternative to the rabbit pyrogen test
Hartung T., Prof.. Dr., Biochemical Pharmacology, University of Konstanz, Germany
 

DIAGNOSTIC APPROACHES: VACCINES

113-08Generic in-vitro evaluation assay for immunological correlates of protection to replace animal challenge infections
Summerfield A., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
85-03Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
72-00Development and applications of an in vitro cultivation model for Neospora caninum tissue cyst formation
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
51-96Establishment of endotoxin limits in porcine vaccines: animal welfare aspects
Cussler K., Dr., Paul Ehrlich Institut, Langen, Germany
 

DIAGNOSTIC APPROACHES: VIRUSES

74-00Validation of polymerase chain reaction assays as replacement of the Mouse Antibody Production (MAP) Test
Bootz F., Dr., Institute of Laboratory Animal Science, University of Zürich, Switzerland
 
45-96Replacement of mouse and rat antibody production test by polymerase chain reaction assays
Homberger F., Prof. Dr., Department of Microbiology and Immunology, Weill Medical College of Cornell University and the Memorial Sloaan-Kettering Center, USA
 

DRUG SCREENING

133-12Development of an in vitro system to grow and investigate vascular endothelial cells under physiological flow conditions
Rieben R., Prof., Department of Clinical Research, University of Bern, Switzerland
 
111-08Establishment of an organ ex-vivo tissue slice model for cardiovascular research in particular for therapeutic atherosclerosis targeting
Hunziker P., PD Dr., Intensive Care Unit, University Hospital Basel, Switzerland
 
110-08Development of an in-vitro assay for the screening of antischistosomal drugs
Keiser J., Prof. Dr., Swiss Tropical Institute, University of Basel,Switzerland
 
100-06Development of an in-vitro system for modeling bioaccumulation of neutral, ionizable, and metabolically active organic pollutants in fish
Escher B., Prof. Dr., Dept. of Environmental Toxicology, EAWAG, Dübendorf, Switzerland
 
82-02Magnetic Resonance Imaging (MRI) for the non-invasive assessment of lung inflammation and pulmonary function in the rat
Beckmann N., PD Dr., Novartis Pharma AG Basel Novartis Institute of Biomedical Research (NIBR), Basel, Switzerland
 
81-02In vitro model for the testing of endothelial cell activation and damage in whole blood
Rieben R., Prof. Dr., Heart Transplantation Laboratory, Cardiology, University Hospital Bern, Switzerland
 

INFECTIOSITY

128-11Genetic modification of the human airway epithelium – a paradigmatic system to study host responses to human respiratory viruses
Thiel V., PD Dr., Institut für Immunbiologie, Kantonsspital St. Gallen, Switzerland
 
124-10Comparative in vitro and in vivo testing on biofilm formation on the surface of bone grafts
Clauss M., Dr., Kantonsspital Liestal, Orthopädie, Liestal, Switzerland
 
118-10Engineering of an in vitro hepatocyte tissue system for malaria liver infection research
Mancama D., Dr., Systems Biology, Biosciences Unit, CSIR, South Africa
 
107-07Evaluation of an in vitro model to identify host parameters associated with virulence of Toxoplasma gondii strains
D’Souza S., Dr., Pasteur Institute of Brussels-ISP,1180-Uccle, Belgium
 
99-05The NEMO network (Non-mammalian Experimental Models for the study of bacterial infections)
Cosson P., Prof. Dr., Département de Physiologie Cellulaire et Métabolisme, Centre Medical Universitaire Genève, Geneva 4, Switzerland
 
90-03A non-mammalian system to study bacterial infections
Cosson P., Prof. Dr., Centre Medical Universitaire, Dpt de Morphologie, Geneva 4, Switzerland
 

IN-VITRO METABOLISM ASSAY

141-14In-vitro alternatives to in-vivo bioconcentration-testing in fish: restricted to rainbow trout or broadly applicable ?
Segner, H., Prof., Centre for Fish and Wildlife Health, Vetsuisse Faculty, University of Bern, Switzerland
 

EFFICACY TEST

136-13Development of an in-vitro potency assay for the Clostridium chauvoei vaccines: Replacement of the guinea-pig-challenge potency test
Frey, J., Prof., Institute of Veterinary Bacteriology, Vetsuisse Faculty, University of Bern, Switzerland
 

NANOMEDICIN

STANDARDIZATION

109-08Evaluation of lipid fractions for the substitution of serum in cell culture media
Honegger P., Prof. Dr., Département de Physiologie, Université de Lausanne, Switzerland
 
77-01Reproducibility and external validity of findings from animal experiments: influence of housing conditions
Würbel H., Prof. Dr., Institute of Laboratory Animal Science, University of Zurich, Switzerland
 

TOXICITY TESTING

TOXICITY TESTING: AEROSOLS

106-07Standardization and Pre-validation of MucilAir: A novel in vitro cell model of the human airway epithelium for testing acute and chronic effects of chemical compounds
Huang S., Dr., Epithelix Sàrl, Plan-les-Ouates, Geneva, Switzerland
 
89-03In vitro replica of the inner surface of the lungs, for the study of particle-cell interaction
Geiser Kamber M., Prof. Dr., Institute of Anatomy, University of Bern, Switzerland
 

TOXICITY TESTING: BIOMATERIALS / IMPLANTS

TOXICITY TESTING: BIODEGRADABLES

TOXICITY TESTING: CARCINOGENICITY

94-04Tumor targeted reporter gene expression to improve and refine traditional models of Tumor growth and metastasis
Vorburger S., Dr., Department of Clinical Research, Visceral and Transplantation Surgery, University Hospital Bern, Switzerland
 

TOXICITY TESTING: CHRONIC EXPOSURE

TOXICITY TESTING: CONTACT ALLERGENS

67-99Human monocyte-derived dendritic cells as in vitro indicators for contact allergic potential of chemicals
Ulrich P., Dr., PCS/GENEX-Experimental Toxicology, Novartis Pharma AG, Basel, Switzerland
 

TOXICITY TESTING: ENDOCRINE DISRUPTORS

TOXICITY TESTING: HAEMATOPOETIC SYSTEM

TOXICITY TESTING: NANO- ULTRAFINE PARTICLES

89-03In vitro replica of the inner surface of the lungs, for the study of particle-cell interaction
Geiser Kamber M., Prof. Dr., Institute of Anatomy, University of Bern, Switzerland
 

TOXICITY TESTING: NEUROTOXINS

138-13Optimization of the nerve-cell-mimicking liposome assay as an in-vitro alternative for the detection of Clostridium-botulinum neurotoxins and for a validation of their presence in complex sample materials
Avondet, M.-A., Toxinology Group, Spiez Laboratory, Switzerland
 
125-11Nerve-cell mimicking liposomes as in vitro alternative to potency-testing of toxins with multistep pathways, such as Botulinum neurotoxins
Weingart O.G., Dr., Institute for Food, Nutrition and Health (IFNH), ETH Zurich, Switzerland;
 

TOXICITY TESTING: PHARMACEUTICALS

125-11Nerve-cell mimicking liposomes as in vitro alternative to potency-testing of toxins with multistep pathways, such as Botulinum neurotoxins
Weingart O.G., Dr., Institute for Food, Nutrition and Health (IFNH), ETH Zurich, Switzerland;
 
75-00Internet laboratory for predicting harmful effects triggered by drugs and chemicals
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland present address: Department of Chemistry, Molecular Modeling. University of Basel, Pharmacenter, 4056 Basel, Switzerland
 
60-97Transgenic protozoa (Trypanosoma spp.) as an alternative to transgenic animals
Roditi I., Prof. Dr., Institutes of General Microbiology and Parasitology, University of Bern, Switzerland
 
55-96Computer-aided identification of ochratoxin antagonists
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland
 
54-96Elaboration of an in vitro screening method for testing the effect of drugs and other compounds on the renal transport of uric acid
Roch-Ramel F., Prof. Dr., Institute of Pharmacoly and Toxicology, University of Lausanne, Switzerland
 
53-96Axenic cultivation of amastigote forms of Leishmania
Grimm F., Dr. phil. nat., Institute of Parasitology, University of Zürich, Switzerland
 
50-96Morphometric Analysis of human articular cartilage
Hunziker E., Prof. Dr., M.E.Müller Institut für Biomechanik, University of Bern, Switzerland
 

TOXICITY TESTING: RECEPTOR MEDIATED

125-11Nerve-cell mimicking liposomes as in vitro alternative to potency-testing of toxins with multistep pathways, such as Botulinum neurotoxins
Weingart O.G., Dr., Institute for Food, Nutrition and Health (IFNH), ETH Zurich, Switzerland;
 
75-00Internet laboratory for predicting harmful effects triggered by drugs and chemicals
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland present address: Department of Chemistry, Molecular Modeling. University of Basel, Pharmacenter, 4056 Basel, Switzerland
 

TOXICITY TESTING: SENSITISING POTENTIAL

67-99Human monocyte-derived dendritic cells as in vitro indicators for contact allergic potential of chemicals
Ulrich P., Dr., PCS/GENEX-Experimental Toxicology, Novartis Pharma AG, Basel, Switzerland
 

TOXICITY TESTING: SENSORY IRRITANTS

70-99Sensory irritant screening using a stable cell line expressing the vanilloid receptor
Baumann T., Prof. Dr., Dept. of Neurological Suregry,Oregon Health and Sciences University, Portland, USA
 

TOXICITY TESTING: XENOBIOTICS

75-00Internet laboratory for predicting harmful effects triggered by drugs and chemicals
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland present address: Department of Chemistry, Molecular Modeling. University of Basel, Pharmacenter, 4056 Basel, Switzerland
 
55-96Computer-aided identification of ochratoxin antagonists
Vedani A., Prof. Dr., Biographics Laboratory 3R, Basel, Switzerland
 
47-96Development of an in vitro system for the detection of estrogenic compounds (xenoestrogens)
Fent K., PD Dr., Swiss Federal Institute for Environmental Science and Technology (EAWAG), Switzerland
 
43-95Short term assay for liver cell activated neurotoxic drugs
Maier P., Prof. Dr., Institute of Toxicology, Swiss Federal Institute of Technology (ETH) and University of Zürich, Switzerland
 

PHARMACOLOGICAL TESTING

69-99A human neural cell line as in vitro model system for the excitotoxic cascade during stroke
Bicker G., Prof. Dr., Abt. Zellbiologie, Physiologisches Institut, Stiftung Tierärztliche Hochschule Hannover, Germany
 

VALIDATION

138-13Optimization of the nerve-cell-mimicking liposome assay as an in-vitro alternative for the detection of Clostridium-botulinum neurotoxins and for a validation of their presence in complex sample materials
Avondet, M.-A., Toxinology Group, Spiez Laboratory, Switzerland
 
137-13Validation of a new human in-vitro model of microglia
Filgueira, L., Prof., Department of Medicine, University of Fribourg, Switzerland
 
106-07Standardization and Pre-validation of MucilAir: A novel in vitro cell model of the human airway epithelium for testing acute and chronic effects of chemical compounds
Huang S., Dr., Epithelix Sàrl, Plan-les-Ouates, Geneva, Switzerland
 
86-03Bone Formation in a loading chamber for ex-vivo bone culture
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 
78-01Validation of a combined perfusion/loading chamber for ex-vivo bone metabolic studies and bone-biomaterial interactions
Richards R.G., Dr., AO Research Institute, Davos, Switzerland
 

VETERINARY DRUGS

105-06Establishment of an in vitro system for the prediction of the degree of virulence of classical swine fever virus isolates
Ruggli N., Dr., Institute of Virology and Immunoprophylaxis (IVI), Mittelhaeusern, Switzerland
 
85-03Development of an in vitro culture model to generate Neospora caninum and Toxoplasma gondii oocysts and sporozoites
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 
79-01Screening methods for repellents and attachment deterrents for ticks in-vitro
Guerin P., PD Dr., Institute of Zoology, University of Neuchâtel, Switzerland
 
72-00Development and applications of an in vitro cultivation model for Neospora caninum tissue cyst formation
Hemphill A., Prof. Dr., Institute of Parasitology, Faculty of Vetsuisse and of Medicine, University of Berne, Switzerland
 


TOP